RxDoctor Payments Data

Mariah Johnson, APRN

Family · Oklahoma City, OKNPI 1124796610

Payments from drug & device makers

$3,737in general payments, 2019–2025

Across 56 payments — averaging $66.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alnylam Pharmaceuticals Inc.$2K
  • Modernatx, Inc.$1K
  • AstraZeneca$248
  • Pulmonx Corporation$177
  • Boehringer Ingelheim$145
  • Lilly USA, LLC$132
  • plus $308 from 12 others

What the payments were for

  • Travel & lodging$2,01354%
  • Food & beverage$1,72546%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,737 in reported general payments places this provider in the 90th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$25,360
Medicare patients
119
Services billed
700

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide92$99,064
EliquisApixaban38$29,154
JardianceEmpagliflozin32$28,578
MounjaroTirzepatide25$25,838
TrulicityDulaglutide15$24,238
RybelsusSemaglutide22$23,799
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$15,212
FarxigaDapagliflozin Propanediol12$13,021
Tresiba Flextouch U-100Insulin Degludec15$11,606
Advair HfaFluticasone Propion/Salmeterol11$5,914
Albuterol Sulfate HfaAlbuterol Sulfate157$4,614
Novolog FlexpenInsulin Aspart14$4,019
Oxybutynin Chloride ErOxybutynin Chloride64$2,468
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$1,711
Gabapentin119$1,570

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$41$122,862114 claims
Lilly USA, LLCMounjaro, Trulicity$132$50,07540 claims
Boehringer IngelheimJardiance$145$28,57832 claims
GSKTrelegy Ellipta$19$15,21219 claims
AstraZenecaFarxiga$248$13,02112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,026 family providers in Oklahoma.

Other family in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →